SIONNA THERAPEUTICS INC (SION) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SION • US8294011080

36.82 USD
+0.71 (+1.97%)
At close: Feb 9, 2026
36.82 USD
0 (0%)
After Hours: 2/9/2026, 4:30:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SION. SION was compared to 523 industry peers in the Biotechnology industry. While SION has a great health rating, there are worries on its profitability. SION does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SION has reported negative net income.
  • In the past year SION has reported a negative cash flow from operations.
SION Yearly Net Income VS EBIT VS OCF VS FCFSION Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -20.83%, SION is doing good in the industry, outperforming 75.53% of the companies in the same industry.
  • The Return On Equity of SION (-21.97%) is better than 82.22% of its industry peers.
Industry RankSector Rank
ROA -20.83%
ROE -21.97%
ROIC N/A
ROA(3y)-56.75%
ROA(5y)N/A
ROE(3y)-75.41%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SION Yearly ROA, ROE, ROICSION Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SION so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SION Yearly Profit, Operating, Gross MarginsSION Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • The number of shares outstanding for SION remains at a similar level compared to 1 year ago.
  • SION has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SION Yearly Shares OutstandingSION Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
SION Yearly Total Debt VS Total AssetsSION Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 54.01 indicates that SION is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of SION (54.01) is better than 96.56% of its industry peers.
  • There is no outstanding debt for SION. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 54.01
ROIC/WACCN/A
WACCN/A
SION Yearly LT Debt VS Equity VS FCFSION Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 25.61 indicates that SION has no problem at all paying its short term obligations.
  • SION's Current ratio of 25.61 is amongst the best of the industry. SION outperforms 97.51% of its industry peers.
  • SION has a Quick Ratio of 25.61. This indicates that SION is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 25.61, SION belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 25.61
Quick Ratio 25.61
SION Yearly Current Assets VS Current LiabilitesSION Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for SION have decreased strongly by -30.53% in the last year.
EPS 1Y (TTM)-30.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SION is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.47% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.09%
EPS Next 2Y-1.78%
EPS Next 3Y-4.8%
EPS Next 5Y-7.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SION Yearly Revenue VS EstimatesSION Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
SION Yearly EPS VS EstimatesSION Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SION reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SION is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SION Price Earnings VS Forward Price EarningsSION Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SION Per share dataSION EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • SION's earnings are expected to decrease with -4.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.78%
EPS Next 3Y-4.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SION does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SIONNA THERAPEUTICS INC

NASDAQ:SION (2/9/2026, 4:30:02 PM)

After market: 36.82 0 (0%)

36.82

+0.71 (+1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-16
Inst Owners67.43%
Inst Owner Change0.29%
Ins Owners1.38%
Ins Owner Change-2.43%
Market Cap1.64B
Revenue(TTM)N/A
Net Income(TTM)-70.68M
Analysts84.29
Price Target45.75 (24.25%)
Short Float %10.21%
Short Ratio9.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.23%
Min EPS beat(2)6.88%
Max EPS beat(2)27.57%
EPS beat(4)2
Avg EPS beat(4)-119.42%
Min EPS beat(4)-476.3%
Max EPS beat(4)27.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.37%
PT rev (3m)18.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.16%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.11
P/tB 5.11
EV/EBITDA N/A
EPS(TTM)-4.87
EYN/A
EPS(NY)-2.3
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS7.21
TBVpS7.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.83%
ROE -21.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.75%
ROA(5y)N/A
ROE(3y)-75.41%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.61
Quick Ratio 25.61
Altman-Z 54.01
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)577.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.5%
EPS Next Y6.09%
EPS Next 2Y-1.78%
EPS Next 3Y-4.8%
EPS Next 5Y-7.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.11%
EBIT Next 3Y-27.67%
EBIT Next 5YN/A
FCF growth 1Y-17.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.8%
OCF growth 3YN/A
OCF growth 5YN/A

SIONNA THERAPEUTICS INC / SION FAQ

What is the fundamental rating for SION stock?

ChartMill assigns a fundamental rating of 3 / 10 to SION.


What is the valuation status for SION stock?

ChartMill assigns a valuation rating of 0 / 10 to SIONNA THERAPEUTICS INC (SION). This can be considered as Overvalued.


Can you provide the profitability details for SIONNA THERAPEUTICS INC?

SIONNA THERAPEUTICS INC (SION) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SIONNA THERAPEUTICS INC?

The Earnings per Share (EPS) of SIONNA THERAPEUTICS INC (SION) is expected to grow by 6.09% in the next year.